Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Chan Y. Cheah et al.|Journal of Clinical Oncology|2023Cited by 106
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37